Patents by Inventor Timothy M. Fan

Timothy M. Fan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Procaspase activating compounds
    Patent number: 9643960
    Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: May 9, 2017
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Quinn Patrick Peterson, Danny Chung Hsu, Diana C. West, Timothy M. Fan, Chris J. Novotny
  • Potent anticancer activity via dual compound activation
    Patent number: 9592229
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods the use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: March 14, 2017
    Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Theodore M. Tarasow
  • PROCASPASE COMBINATION THERAPY FOR GLIOBLASTOMA
    Publication number: 20170042886
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Application
    Filed: August 22, 2016
    Publication date: February 16, 2017
    Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc., The Johns Hopkins University
    Inventors: Paul J. HERGENROTHER, Rachel C. BOTHAM, Timothy M. FAN, Mark J. GILBERT, Michael J. Handley, Avadhut JOSHI, Gregory J. RIGGINS, Theodore M. TARASOW
  • PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY
    Publication number: 20160346277
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Application
    Filed: July 26, 2016
    Publication date: December 1, 2016
    Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.
    Inventors: Paul J. HERGENROTHER, Rachel C. BOTHAM, Timothy M. FAN, Mark J. GILBERT, Michael K. HANDLEY, Howard S. ROTH, Theodore M. TARASOW
  • Procaspase combination therapy for glioblastoma
    Patent number: 9421202
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: August 23, 2016
    Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc., The Johns Hopkins University
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael J. Handley, Avadhut Joshi, Gregory J. Riggins, Theodore M. Tarasow
  • Procaspase 3 activation by combination therapy
    Patent number: 9399035
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: July 26, 2016
    Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
  • PROCASPASE ACTIVATING COMPOUNDS
    Publication number: 20150344452
    Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.
    Type: Application
    Filed: August 10, 2015
    Publication date: December 3, 2015
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Quinn Patrick Peterson, Danny Chung Hsu, Diana C. West, Timothy M. Fan, Chris J. Novotny
  • Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
    Patent number: 9102661
    Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: August 11, 2015
    Assignee: The Board of Trustees of the University Illinois
    Inventors: Paul J. Hergenrother, Quinn Patrick Peterson, Danny Chung Hsu, Diana C. West, Timothy M. Fan, Chris J. Novotny
  • POTENT ANTICANCER ACTIVITY VIA DUAL COMPOUND ACTIVATION
    Publication number: 20150099759
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods the use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Application
    Filed: March 4, 2013
    Publication date: April 9, 2015
    Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Theodore M. Tarasow
  • PROCASPASE COMBINATION THERAPY FOR GLIOBLASTOMA
    Publication number: 20150025083
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Application
    Filed: March 6, 2013
    Publication date: January 22, 2015
    Applicants: THE JOHNS HOPKINS UNIVERSITY, VANQUISH ONCOLOGY, INC.
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael J. Handley, Avadhut Joshi, Gregory J. Riggins, Theodore M. Tarasow
  • PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY
    Publication number: 20150017264
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Application
    Filed: March 6, 2013
    Publication date: January 15, 2015
    Applicants: Vanquish Oncology, Inc., TheBoard of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
  • DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS
    Publication number: 20140315915
    Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.
    Type: Application
    Filed: July 1, 2014
    Publication date: October 23, 2014
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Quinn Patrick Peterson, Danny Chung Hsu, Diana C. West, Timothy M. Fan, Chris J. Novotny
  • Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
    Patent number: 8778945
    Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: July 15, 2014
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Paul Joseph Hergenrother, Quinn Patrick Peterson, Danny Chung Hsu, Diana C. West, Timothy M. Fan, Chris J. Novotny
  • DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS
    Publication number: 20120040995
    Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.
    Type: Application
    Filed: February 9, 2010
    Publication date: February 16, 2012
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Paul J. Hergenrother, Quinn Patrick Peterson, Danny Chung Hsu, Diana C. West, Timothy M. Fan, Chris J. Novotny